Impact of an Oligomeric Diet in Intestinal Absorption and Inflammatory Markers in Patients With Crohn Disease
Clinical Trial to Evaluate the Effect of an Oligomeric Oral Nutritional Supplement on the Response in Intestinal Absorption and Inflammation, in Patients With CROHN Disease
Sponsor: Adventia Pharma
A NA clinical study on Absorption; Disorder and Absorption; Disorder, Carbohydrate, this trial is ongoing. The trial is conducted by Adventia Pharma and has accumulated 6 data snapshots since 2020. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Unknown NA
-
Jul 2024 — Sep 2024 [monthly]
Unknown NA
Status: Unknown Status → Unknown
-
Feb 2023 — Jul 2024 [monthly]
Unknown Status NA
-
Apr 2022 — Feb 2023 [monthly]
Unknown Status NA
Status: Recruiting → Unknown Status
-
Jan 2021 — Apr 2022 [monthly]
Recruiting NA
▶ Show 1 earlier version
-
Apr 2020 — Jan 2021 [monthly]
Recruiting NA
First recorded
Feb 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Adventia Pharma
- Biopolis S.L.
- Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz
For direct contact, visit the study record on ClinicalTrials.gov .